Magnetic Fields Cancer Research Results

MF, Magnetic Fields: Click to Expand ⟱
Features: Therapy
Magnetic Fields can be Static, or pulsed. The most common therapy is a pulsed magnetic field in the uT or mT range.
The main pathways affected are:
Calcium Signaling: -influence the activity of voltage-gated calcium channels.
Oxidative Stress and Reactive Oxygen Species (ROS) Pathways
Heat Shock Proteins (HSPs) and Cellular Stress Responses
Cell Proliferation and Growth Signaling: MAPK/ERK pathway.
Gene Expression and Epigenetic Modifications: NF-κB
Angiogenesis Pathways: VEGF (improving VEGF for normal cells)
PEMF was found to have a 2-fold increase in drug uptake compared to traditional electrochemotherapy in rat melanoma models

Pathways:
- most reports have ROS production increasing in cancer cells , while decreasing in normal cells.
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓, Prx,
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, Pro-Inflammatory Cytokines : NLRP3↓, IL-1β↓, TNF-α↓, IL-6↓, IL-8↓
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, VEGF↓(mostly regulated up in normal cells),
- cause Cell cycle arrest : TumCCA↑,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓,
- inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, GLUT1↓, LDH↓, HK2↓, PFKs↓, PDKs↓, ECAR↓, OXPHOS↓, GRP78↑, Glucose↓, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, FGF↓, PDGF↓, EGFR↓, Integrins↓,
- Others: PI3K↓, AKT↓, STAT↓, Wnt↓, β-catenin↓, ERK↓, JNK, - SREBP (related to cholesterol).
- Synergies: chemo-sensitization, chemoProtective, cytoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells

Non-Static Magnetic Fields (AC / Pulsed / Oscillating MF)
Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Reactive oxygen species (ROS) ↑ ROS (P→R); often sustained (G) ↑ ROS (P); ↔/↓ net ROS (R→G) P, R, G Upstream redox perturbation MF perturbs electron/radical dynamics: normal cells often adapt (ROS setpoint ↓), cancer cells less so
2 NRF2 antioxidant response ↔ / insufficient NRF2 induction (R→G) ↑ NRF2 activation (R→G) R, G Adaptive redox defense Explains mixed ROS direction in normal cells (initial ↑ then adaptive ↓)
3 Glutathione (GSH) homeostasis ↓ GSH (R→G) ↔ or transient ↓ (R) with recovery (G) R, G Redox buffering capacity GSH depletion reflects sustained oxidative load; recovery indicates successful adaptation
4 Superoxide dismutase (SOD) / antioxidant enzymes ↔ or inadequate enzyme upshift (G) ↑ SOD/GPx/CAT capacity (G) G Longer-term antioxidant remodeling Often the “endpoint” readout that correlates with ROS-normalization in normal tissue
5 Mitochondrial ETC / respiration ↓ ETC efficiency; ↑ electron leak (P→R) ↔ mild, reversible ETC perturbation (P→R) P, R Bioenergetic destabilization ETC perturbation is a mechanistic bridge between MF exposure and ROS/ΔΨm changes
6 Mitochondrial membrane potential (ΔΨm / MMP) ↓ ΔΨm (R); may progress (G) ↔ preserved or reversible dip (R) R, G Mitochondrial dysfunction thresholding ΔΨm loss typically follows ROS/ETC disruption rather than preceding it
7 Ca²⁺ signaling (VGCC / ER–mitochondria Ca²⁺ flux) ↑ dysregulated Ca²⁺ influx/transfer (P→R); overload may persist (G) ↑ transient Ca²⁺ signaling (P); homeostasis restored (R→G) P, R, G Stress signal amplification Ca²⁺ dysregulation links ROS/ETC perturbation to ER stress and mitochondrial dysfunction (amplifies ΔΨm loss and UPR commitment)
8 Mitochondrial permeability transition pore (MPTP) ↑ MPTP opening propensity (R); sustained opening possible (G) ↔ transient or closed (R→G) P, R, G Commitment point for mitochondrial failure MPTP opening integrates ROS, Ca²⁺ overload, and ΔΨm loss; acts as a threshold event converting reversible stress into irreversible mitochondrial dysfunction
9 ER stress / UPR ↑ ER stress (R); CHOP-commitment possible (G) ↑ adaptive UPR (R); resolves (G) R, G Proteostasis stress Often downstream of ROS + Ca²⁺ handling perturbations
10 DNA damage (oxidative) ↑ damage markers (R→G) ↔ or repaired (G) R, G Checkpoint pressure Generally secondary to ROS; interpret as stress consequence not “direct genotoxicity”
11 LDH / glycolytic flux ↓ glycolytic performance (R→G) ↔ flexible substrate switching (R→G) R, G Metabolic vulnerability Redox imbalance can destabilize high-rate glycolysis in cancer-biased contexts
12 Thioredoxin system (Trx / TrxR) ↓ functional reserve / overload (R→G) ↔ preserved capacity (G) R, G Parallel antioxidant system stress Useful when GSH-only does not explain redox phenotype
Time-Scale Flag: TSF = P / R / G
  P: 0–30 min (physical / electron / radical effects)
  R: 30 min–3 hr (redox signaling & stress response)
  G: >3 hr (gene-regulatory adaptation)
MPTP: opening represents a mitochondrial commitment event integrating ROS and Ca²⁺ stress; sustained opening indicates irreversible bioenergetic failure.


Scientific Papers found: Click to Expand⟱
6941- MF,  Ex,    The effects of pulsed electromagnetic field therapy on muscle strength and pain in patients with end-stage knee osteoarthritis: a randomized controlled trial
- Trial, Arthritis, NA
*Strength↑, *Pain↓, *eff↑, *Dose↝,
6940- MF,    Meta-analysis of the effectiveness and safety of magnetic stimulation for chronic pelvic pain
- Review, BPH, NA
*UFR↑, *other?, *Pain↓, *BloodF↑, *other↑, *Inflam↓, *QoL↑,
6939- MF,    A prospective, randomized, placebo controlled, double-blind study of pelvic electromagnetic therapy for the treatment of chronic pelvic pain syndrome with 1 year of followup
- Trial, Nor, NA
*Pain↓,
6938- MF,    Effect of pulsed electromagnetic field therapy on prostate volume and vascularity in the treatment of benign prostatic hyperplasia: a pilot study in a canine model
- in-vivo, BPH, NA
*Dose↝, *toxicity↓, *BloodF↑, *Dose↝, *PV↓, *Inflam↓,
6937- MF,    Noninvasive treatment for men suffering from enlarged prostate
- Review, BPH, NA
*PV↓, *Inflam↓, *BloodF↑, *Dose↝,
6936- MF,  Ex,    Pulsed electromagnetic field with or without exercise therapy in the treatment of benign prostatic hyperplasia
- Trial, BPH, NA
*eff↑, *eff↑, *BloodF↑, *Diff↝, *Dose↝, *Dose↝, *Dose↝, *Dose↝, *Dose↝, *Dose↝, *Dose↝, *UFR↑, *UR↓, *PSA↓, *other↑, *Inflam↓,
4097- MF,    Theta Frequency Electromagnetic Stimulation Enhances Functional Recovery After Stroke
- Trial, Stroke, NA
*motorD↑, *eff↑, *Dose↝,
5533- MF,    Magnetic field-induced drug permeability in liposome vesicles
- in-vitro, Nor, NA
*Dose↝, *CellMemb↑, *other↝,
5532- MF,    Magnetoporation: New Method for Permeabilization of Cancerous Cells to Hydrophilic Drugs
- in-vivo, BC, NA
Dose↑, CellMemb↑, eff↝, other↝, TumCG↓,
5531- MF,    Effect of low frequency, low amplitude magnetic fields on the permeability of cationic liposomes entrapping carbonic anhydrase: I. Evidence for charged lipid involvement
- in-vitro, NA, NA
Dose↝, CellMemb↑,
5247- MF,    Anticancer Activity by Magnetic Fields: Inhibition of Metastatic Spread and Growth in a Breast Cancer Model
- in-vivo, BC, MDA-MB-468
TumCI↓,
5246- MF,  Chemo,    Non-ionizing Electromagnetic Radiation: A Study of Carcinogenic and Cancer Treatment Potential
- in-vitro, BC, MCF7
ChemoSen↑,
5241- MF,    A review on the use of magnetic fields and ultrasound for non-invasive cancer treatment
- Review, Var, NA
other↑, BloodF↑, Glycolysis↓, ATP↓, VEGF↓, ROS↑, P-gp/ABCB1↓, Apoptosis↑, selectivity↑, Ca+2↑, Catalase↑,
5240- MF,    Effect of low frequency magnetic fields on the growth of MNP-treated HT29 colon cancer cells
- in-vitro, Colon, HT29
TumCP⇅,
4571- MF,    Magnetic Fields and Reactive Oxygen Species
- Review, NA, NA
*ROS⇅, *ETC↓, Dose↝, Dose↝,
4568- MF,    Extremely low-frequency pulses of faint magnetic field induce mitophagy to rejuvenate mitochondria
- Study, NA, NA
*ETC↓, *OCR↑, *MMP↑, *ROS⇅, *MMP⇅,
4425- MF,  doxoR,    Brief Magnetic Field Exposure Stimulates Doxorubicin Uptake into Breast Cancer Cells in Association with TRPC1 Expression: A Precision Oncology Methodology to Enhance Chemotherapeutic Outcome
- in-vitro, BC, 4T1 - in-vitro, BC, MCF7
ChemoSen↑, TRPC1↑, Dose↓, selectivity↑,
4356- MF,    Pulsed electromagnetic fields synergize with graphene to enhance dental pulp stem cell-derived neurogenesis by selectively targeting TRPC1 channels
- in-vitro, Nor, NA
*Diff↑, *TRPC1↑, *ROS↑,
4355- MF,    Ambient and supplemental magnetic fields promote myogenesis via a TRPC1-mitochondrial axis: evidence of a magnetic mitohormetic mechanism
- in-vitro, Nor, C2C12
*mt-OCR↑, *mt-ROS↑, *ECAR↑, *Dose↝, *Ca+2↑, *ATP↑, *other↑, *eff↓, *eff↝,
4354- MF,  doxoR,    Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach
- in-vivo, BC, MDA-MB-231 - in-vivo, BC, MCF7
selectivity↑, Apoptosis↑, TumCI↓, tumCV↓, TumVol↓, eff↓, eff↑, ROS↑, Ca+2↑, TumCMig↓,
3485- MF,    Cytoprotective effects of low-frequency pulsed electromagnetic field against oxidative stress in glioblastoma cells
- in-vitro, GBM, U87MG
*antiOx↑, *ROS↓, *cytoP↑,
3724- MF,  RF,    Electromagnetic Field in Alzheimer's Disease: A Literature Review of Recent Preclinical and Clinical Studies
- Review, AD, NA
*memory↑, *neuroP↑,
3569- MF,    Current Evidence Using Pulsed Electromagnetic Fields in Osteoarthritis: A Systematic Review
- Review, Arthritis, NA
*Pain↓, *QoL↑, *motorD↑,
3568- MF,    The Efficacy of Pulsed Electromagnetic Fields on Pain, Stiffness, and Physical Function in Osteoarthritis: A Systematic Review and Meta-Analysis
- Review, Arthritis, NA
*eff↑, *Pain↓, *motorD↑,
3566- MF,    Positive and Negative Effects of Administering a Magnetic Field to Patients with Rheumatoid Arthritis (RA)
- Study, Arthritis, NA
*Inflam↓, *QoL↑, *Pain↓, *motorD↑, *toxicity↓, *Cartilage↑, *Inflam↓,
3474- MF,    Pulsed electromagnetic fields potentiate the paracrine function of mesenchymal stem cells for cartilage regeneration
- in-vitro, Nor, NA
*Inflam↓, *Apoptosis↓, *other↑, *PGE2↓, *COX2/PTGS2↓, *IL6↓, *IL8↓, *cAMP↑, *IL10↑,
3501- MF,    Unveiling the Power of Magnetic-Driven Regenerative Medicine: Bone Regeneration and Functional Reconstruction
- Review, NA, NA
*VEGF↑, *BMPs↓, *SMAD4↑, *SMAD5↑, *Ca+2↑,
3500- MF,    Moderate Static Magnet Fields Suppress Ovarian Cancer Metastasis via ROS-Mediated Oxidative Stress
- in-vitro, Ovarian, SKOV3
ROS↑, CSCs↓, CD44↓, SOX2↓, cMyc↓, TumMeta↓, TumCI↓, TumCMig↓, CD133↓, Nanog↓,
3498- MF,    Effect of Static Magnetic Field on Oxidant/Antioxidant Parameters in Cancerous and Noncancerous Human Gastric Tissues
- in-vitro, GC, NA
*SOD↑, *MDA↓, SOD↓, GPx↓, MDA↑, Catalase↑,
3487- MF,  Rad,    High-specificity protection against radiation-induced bone loss by a pulsed electromagnetic field
- Review, Var, NA
radioP↑, *Ca+2↑, RAS↑, MAPK↓,
3486- MF,    Pulsed electromagnetic field potentiates etoposide-induced MCF-7 cell death
- in-vitro, NA, NA
ChemoSen↑, tumCV↓, cl‑PARP↑, Casp7↑, Casp9↑, survivin↓, BAX↑, DNAdam↑, ROS↑, eff↓,
3536- MF,    Targeting Mesenchymal Stromal Cells/Pericytes (MSCs) With Pulsed Electromagnetic Field (PEMF) Has the Potential to Treat Rheumatoid Arthritis
- Review, Arthritis, NA - Review, Stroke, NA
*Inflam↓, *Diff↑, *toxicity∅, *other↑, *SOX9↑, *COL2A1↑, *NO↓, *PGE2↓, *NF-kB↓, *TNF-α↓, *IL1β↓, *IL6↓, *IL10↑, *angioG↑, *MSCs↑, *VEGF↑, *TGF-β↑, *angioG↝, *VEGF↓, Ca+2↝,
3484- MF,    Extremely low frequency pulsed electromagnetic fields cause antioxidative defense mechanisms in human osteoblasts via induction of •O2 − and H2O2
- in-vitro, Nor, NA
*GPx↑, *SOD2↑, *Catalase↑, *GSR↑, *ROS↓,
3483- MF,    Pulsed Electromagnetic Fields Protect Against Brain Ischemia by Modulating the Astrocytic Cholinergic Anti-inflammatory Pathway
- NA, Stroke, NA
*Inflam↓, *STAT3↓, *p‑STAT3↓,
3482- MF,    Pulsed Electromagnetic Fields Increase Angiogenesis and Improve Cardiac Function After Myocardial Ischemia in Mice
- in-vitro, NA, NA
*cardioP↑, *VEGF↑, *VEGFR2/KDR/Flk1↑, *Hif1a↑, *FGF↑, *ITGB1↑, *angioG↑,
3481- MF,    No effects of pulsed electromagnetic fields on expression of cell adhesion molecules (integrin, CD44) and matrix metalloproteinase-2/9 in osteosarcoma cell lines
- in-vitro, OS, MG63 - in-vitro, OS, SaOS2
ITGA1∅, ITGB1∅, ITGA5∅, ITGB3∅, ITGB4∅, MMP2∅, MMP9∅, eff↑,
3480- MF,    Cellular and Molecular Effects of Magnetic Fields
- Review, NA, NA
ROS↑, *Ca+2↑, *Inflam↓, *Akt↓, *mTOR↓, selectivity↑, *memory↑, *MMPs↑, *VEGF↑, *FGF↑, *PDGF↑, *TNF-α↑, *HGF/c-Met↑, *IL1↑,
3479- MF,    Evaluation of Pulsed Electromagnetic Field Effects: A Systematic Review and Meta-Analysis on Highlights of Two Decades of Research In Vitro Studies
- Review, NA, NA
*eff↓, eff↝, *Hif1a↑, *VEGF↑, *TIMP1↑, *E2Fs↑, *MMP2↑, *MMP9↑, Apoptosis↑,
3478- MF,    One Month of Brief Weekly Magnetic Field Therapy Enhances the Anticancer Potential of Female Human Sera: Randomized Double-Blind Pilot Study
- Trial, BC, NA - in-vitro, BC, MCF7 - in-vitro, Nor, C2C12
TumCP↓, TumCMig↓, TumCI↓, *toxicity∅, TGF-β↓, Twist↓, Slug↓, β-catenin/ZEB1↓, Vim↓, p‑SMAD2↓, p‑SMAD3↓, angioG↓, VEGF↓, selectivity↑, LIF↑,
3477- MF,    Electromagnetic fields regulate calcium-mediated cell fate of stem cells: osteogenesis, chondrogenesis and apoptosis
- Review, NA, NA
*Ca+2↑, *VEGF↑, *angioG↑, Ca+2↑, ROS↑, Necroptosis↑, TumCCA↑, Apoptosis↑, *ATP↑, *FAK↑, *Wnt↑, *β-catenin/ZEB1↑, *ROS↑, p38↑, MAPK↑, β-catenin/ZEB1↓, CSCs↓, TumCP↓, ROS↑, RadioS↑, Ca+2↑, eff↓, NO↑,
3476- MF,    Pulsed Electromagnetic Fields Stimulate HIF-1α-Independent VEGF Release in 1321N1 Human Astrocytes Protecting Neuron-like SH-SY5Y Cells from Oxygen-Glucose Deprivation
- in-vitro, Stroke, 1321N1 - in-vitro, Park, NA
*VEGF↑, *eff↑, *neuroP↑, *other↑, *eff↑, *Inflam↓, *Hif1a∅,
3475- MF,    A Pulsed Electromagnetic Field Protects against Glutamate-Induced Excitotoxicity by Modulating the Endocannabinoid System in HT22 Cells
- in-vitro, Nor, HT22 - Review, AD, NA
*Apoptosis↓, *LDH↓, *neuroP↑, *toxicity∅, *IL1β↓, *Inflam↓, *IL10↑, *TNF-α↓,
3726- MF,    Spatial memory recovery in Alzheimer's rat model by electromagnetic field exposure
- in-vivo, AD, NA
*memory↑, *cognitive↑,
4096- MF,    Extremely Low‐Frequency and Low‐Intensity Electromagnetic Field Technology (ELF‐EMF) Sculpts Microtubules
- in-vitro, AD, NA
*p‑tau↓, *neuroP↑, *Dose↝,
4095- MF,    Frequency-tuned electromagnetic field therapy improves post-stroke motor function: A pilot randomized controlled trial
- Trial, Stroke, NA
*Dose↝, *motorD↑,
4094- MF,    EMAGINE-Study protocol of a randomized controlled trial for determining the efficacy of a frequency tuned electromagnetic field treatment in facilitating recovery within the subacute phase following ischemic stroke
- Study, Stroke, NA
*neuroP↑, *Dose↝,
4093- MF,    Low-intensity electromagnetic fields induce human cryptochrome to modulate intracellular reactive oxygen species
- in-vivo, NA, NA
*ROS↑, *eff↑,
4092- MF,    Mechanisms and therapeutic effectiveness of pulsed electromagnetic field therapy in oncology
- Review, Var, NA
Apoptosis↑, selectivity↑, ROS↑, Catalase↓, TumVol↓, angioG↓, Ca+2↝, eff↝, angioG↓, Imm↝, TNF-α↑, Casp8↑,
4015- MF,    Evaluation of the PTEN and circRNA-CDR1as Gene Expression Changes in Gastric Cancer and Normal Cell Lines Following the Exposure to Weak and Moderate 50 Hz Electromagnetic Fields
- in-vitro, GC, AGS - in-vitro, Nor, HU02
*PTEN↑, PTEN↓, Dose↝,
3942- MF,    Chronic-Exposure Low-Frequency Magnetic Fields (Magnetotherapy and Magnetic Stimulation) Influence Serum Serotonin Concentrations in Patients with Low Back Pain-Clinical Observation Study
- Human, AD, NA
*5HT↑,

Showing Research Papers: 151 to 200 of 275
Prev Page 4 of 6 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 275

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1)

Catalase↓, 1,   Catalase↑, 2,   GPx↓, 1,   MDA↑, 1,   ROS↑, 8,   SOD↓, 1,  

Mitochondria & Bioenergetics(tgid=3)

ATP↓, 1,  

Core Metabolism/Glycolysis(tgid=4)

cMyc↓, 1,   Glycolysis↓, 1,  

Cell Death(tgid=5)

Apoptosis↑, 5,   BAX↑, 1,   Casp7↑, 1,   Casp8↑, 1,   Casp9↑, 1,   MAPK↓, 1,   MAPK↑, 1,   Necroptosis↑, 1,   p38↑, 1,   survivin↓, 1,  

Transcription & Epigenetics(tgid=7)

other↑, 1,   other↝, 1,   tumCV↓, 2,  

DNA Damage & Repair(tgid=10)

DNAdam↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence(tgid=11)

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12)

CD133↓, 1,   CD44↓, 1,   CSCs↓, 2,   Nanog↓, 1,   PTEN↓, 1,   RAS↑, 1,   SOX2↓, 1,   TumCG↓, 1,  

Migration(tgid=13)

Ca+2↑, 4,   Ca+2↝, 2,   ITGA1∅, 1,   ITGA5∅, 1,   ITGB1∅, 1,   ITGB3∅, 1,   ITGB4∅, 1,   MMP2∅, 1,   MMP9∅, 1,   Slug↓, 1,   p‑SMAD2↓, 1,   p‑SMAD3↓, 1,   TGF-β↓, 1,   TRPC1↑, 1,   TumCI↓, 4,   TumCMig↓, 3,   TumCP↓, 2,   TumCP⇅, 1,   TumMeta↓, 1,   Twist↓, 1,   Vim↓, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature(tgid=14)

angioG↓, 3,   NO↑, 1,   VEGF↓, 2,  

Barriers & Transport(tgid=15)

CellMemb↑, 2,   P-gp/ABCB1↓, 1,  

Immune & Inflammatory Signaling(tgid=16)

Imm↝, 1,   LIF↑, 1,   TNF-α↑, 1,  

Drug Metabolism & Resistance(tgid=21)

ChemoSen↑, 3,   Dose↓, 1,   Dose↑, 1,   Dose↝, 4,   eff↓, 3,   eff↑, 2,   eff↝, 3,   RadioS↑, 1,   selectivity↑, 6,  

Clinical Biomarkers(tgid=22)

BloodF↑, 1,  

Functional Outcomes(tgid=23)

radioP↑, 1,   TumVol↓, 2,  
Total Targets: 75

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0)

PV↓, 2,   UFR↑, 2,   UR↓, 1,  

Redox & Oxidative Stress(tgid=1)

antiOx↑, 1,   Catalase↑, 1,   GPx↑, 1,   GSR↑, 1,   MDA↓, 1,   ROS↓, 2,   ROS↑, 3,   ROS⇅, 2,   mt-ROS↑, 1,   SOD↑, 1,   SOD2↑, 1,  

Mitochondria & Bioenergetics(tgid=3)

ATP↑, 2,   ETC↓, 2,   MMP↑, 1,   MMP⇅, 1,   OCR↑, 1,   mt-OCR↑, 1,  

Core Metabolism/Glycolysis(tgid=4)

cAMP↑, 1,   ECAR↑, 1,   LDH↓, 1,  

Cell Death(tgid=5)

Akt↓, 1,   Apoptosis↓, 2,   HGF/c-Met↑, 1,  

Kinase & Signal Transduction(tgid=6)

SOX9↑, 1,  

Transcription & Epigenetics(tgid=7)

other?, 1,   other↑, 6,   other↝, 1,  

Cell Cycle & Senescence(tgid=11)

E2Fs↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12)

Diff↑, 2,   Diff↝, 1,   FGF↑, 2,   MSCs↑, 1,   mTOR↓, 1,   PTEN↑, 1,   STAT3↓, 1,   p‑STAT3↓, 1,   Wnt↑, 1,  

Migration(tgid=13)

Ca+2↑, 5,   Cartilage↑, 1,   COL2A1↑, 1,   FAK↑, 1,   ITGB1↑, 1,   MMP2↑, 1,   MMP9↑, 1,   MMPs↑, 1,   PDGF↑, 1,   SMAD4↑, 1,   SMAD5↑, 1,   TGF-β↑, 1,   TIMP1↑, 1,   TRPC1↑, 1,   β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature(tgid=14)

angioG↑, 3,   angioG↝, 1,   Hif1a↑, 2,   Hif1a∅, 1,   NO↓, 1,   VEGF↓, 1,   VEGF↑, 7,   VEGFR2/KDR/Flk1↑, 1,  

Barriers & Transport(tgid=15)

CellMemb↑, 1,  

Immune & Inflammatory Signaling(tgid=16)

COX2/PTGS2↓, 1,   IL1↑, 1,   IL10↑, 3,   IL1β↓, 2,   IL6↓, 2,   IL8↓, 1,   Inflam↓, 12,   NF-kB↓, 1,   PGE2↓, 2,   PSA↓, 1,   TNF-α↓, 2,   TNF-α↑, 1,  

Synaptic & Neurotransmission(tgid=18)

5HT↑, 1,   p‑tau↓, 1,  

Drug Metabolism & Resistance(tgid=21)

Dose↝, 17,   eff↓, 2,   eff↑, 8,   eff↝, 1,  

Clinical Biomarkers(tgid=22)

BloodF↑, 4,   BMPs↓, 1,   IL6↓, 2,   LDH↓, 1,   PSA↓, 1,  

Functional Outcomes(tgid=23)

cardioP↑, 1,   cognitive↑, 1,   cytoP↑, 1,   memory↑, 3,   motorD↑, 5,   neuroP↑, 5,   Pain↓, 6,   QoL↑, 3,   Strength↑, 1,   toxicity↓, 2,   toxicity∅, 3,  
Total Targets: 98

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:172  Target#:%  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page